Show simple item record

AuthorThaventhiran T.
AuthorWong W.
AuthorAlghanem A.F.
AuthorAlhumeed N.
AuthorAljasir M.A.
AuthorRamsey S.
AuthorSethu S.
AuthorYeang H.X.A.
AuthorChadwick A.E.
AuthorCross M.
AuthorWebb S.D.
AuthorDjouhri L.
AuthorBall C.
AuthorStebbings R.
AuthorSathish J.G.
Available date2020-04-16T06:56:46Z
Publication Date2019
Publication NameMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
ResourceScopus
ISSN21679436
URIhttp://dx.doi.org/10.1089/mab.2018.0042
URIhttp://hdl.handle.net/10576/14207
AbstractCD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4+ effector memory T cells (TEMs) in humans with unwanted serious adverse effects. It is well known that distinct metabolic programs determine the fate and responses of immune cells. In this study, we show that human CD4+ TEMs stimulated with CD28SA adopt a metabolic program similar to those of tumor cells with enhanced glucose utilization, lipid biosynthesis, and proliferation in hypoxic conditions. Identification of metabolic profiles underlying hyperactive T cell activation would provide a platform to test safety of immunostimulatory antibodies.
SponsorThis work was supported by funding from the Medical Research Council, United Kingdom (G1000397-2/1).
Languageen
PublisherMary Ann Liebert Inc.
SubjectCD28 superagonist
CD4+ effector memory T cells
glycolysis
lipogenesis
oxidative phosphorylation
TitleCD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
TypeArticle
Pagination60-69
Issue Number2
Volume Number38
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record